Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 12, Issue 11, 2006, Pages 1058-1067

  Zahn, Alexandra ^a   Hinz, Ulf ^b   Karner, Max ^a   Ehehalt, Robert ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical and endoscopic activity indexes; Health related quality of life; Inflammatory Bowel Disease Questionnaire Deutschland; Phosphatidylcholine; Ulcerative colitis

Indexed keywords

PHOSPHATIDYLCHOLINE; PLACEBO;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DEMOGRAPHY; ENDOSCOPY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHATIDYLCHOLINES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750520733     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000234134.35713.d2     Document Type: Article

References (21)

1. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-454.
2. Casellas F, Lopez-Vivancos J, Badia X, et al. Impact of surgery for Crohn's disease on health-related quality of life. Am J Gastroenterol. 2000;95:177-182.
3. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810.
4. Irvine EJ. Quality of life-measurement in inflammatory bowel disease. Scand J Gastroenterol. 1993;199(suppl):36-39.
5. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease: Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
6. Moskovitz DN, Maunder RG, Cohen Z, et al. Coping behavior and social support contribute independently to quality of life after surgery for inflammatory bowel disease. Dis Colon Rectum. 2000;43:517-521.
7. Cuntz U, Welt J, Ruppert E, et al. Determination of subjective burden from chronic inflammatory bowel disease and its psychosocial consequences: results from a study of 200 patients. Psychother Psychosom Med Psychol. 1999;49:494-500.
8. Hjortswang H, Strom M, Almeida RT, et al. Evaluation of the RFIPC, a disease-specific health-related quality of life questionnaire, in Swedish patients with ulcerative colitis. Scand J Gastroenterol. 1997;32:1235-1240.
9. Kim WH, Cho YS, Yoo HM, et al. Quality of life in Korean patients with inflammatory bowel diseases: ulcerative colitis, Crohn's disease and intestinal Behcet's disease. Int J Colorectal Dis. 1999;14:52-57.
10. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
11. Casellas F, Lopez-Vivancos J, Badia X, et al. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001;13:567-572.
12. Casellas F, Lopez-Vivancos J, Casado A, et al. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002;11:775-781.
13. Maunder R, Toner B, de Rooy E, et al. Influence of sex and disease on illness-related concerns in inflammatory bowel disease. Can J Gastroenterol. 1999;13:728-732.
14. Irvine EJ. Quality of life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol. 1995;208:136-140.
15. Stremmel W, Merle U, Zahn A, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005;54:966-971.
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
17. Hauser W, Dietz N, Grandt D, et al.Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Z Gastroenterol. 2004;42:131-139.
18. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of doubleblind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995;40:931-935.
19. Konig HH, Ulshofer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1205-1215.
20. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, MattsonME, Furberg CF, et al., eds. Clinical Trials of Cardiovascular Therapies. Darien, Conn: Le Jacq Publishing Inc; 1984:170-183.
21. Han SW, McColl E, Steen N, et al. The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the north east of England. Scand J Gastroenterol. 1998;33:961-966.